Literature DB >> 10811480

Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody.

S Paul1, N Bizouarne, K Dott, L Ruet, P Dufour, R B Acres, M P Kieny.   

Abstract

Cytotoxicity is an important function of the immune system that results in the destruction of cellular targets by humoral and/or cellular mechanisms. We wanted to assess the possibility of targeting the lytic function of immune cells toward cancer cells, which express the gene coding for a known tumor antigen (Ag) (GA733-2/epithelial cell adhesion molecule), using a viral vector encoding a monoclonal antibody (mAb) specific for said tumor Ag (CO17-1A). To this end, we have constructed recombinant vaccinia viruses expressing the sequences corresponding to mAb CO17-1A, which recognizes a specific Ag (GA733-2) that is present on the surface of most gastrointestinal carcinomas. The recombinant vectors encoding either a secreted or membrane-anchored form of CO17-1A mAb were used to infect effector cells, which were subsequently assessed for their cytotoxic activity. The recombinant viruses were able to infect both granulocyte-macrophage colony-stimulating factor-activated human macrophages and Ag-stimulated murine cytotoxic T lymphocytes. Infected granulocyte-macrophage colony-stimulating factor-activated macrophages were found to be able to kill GA733-2-expressing tumor cells. Likewise, infected cytotoxic T lymphocytes, although conserving their original alloreactivity, gained the capability of killing GA733-2-expressing cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811480     DOI: 10.1038/sj.cgt.7700161

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  5 in total

1.  HIV-1-based defective lentiviral vectors efficiently transduce human monocytes-derived macrophages and suppress replication of wild-type HIV-1.

Authors:  Lingbing Zeng; Vicente Planelles; Ziye Sui; Suzanne Gartner; Sanjay B Maggirwar; Stephen Dewhurst; Linbai Ye; Vivek R Nerurkar; Richard Yanagihara; Yuanan Lu
Journal:  J Gene Med       Date:  2006-01       Impact factor: 4.565

2.  T cell avidity and tumor recognition: implications and therapeutic strategies.

Authors:  Mark D McKee; Jeffrey J Roszkowski; Michael I Nishimura
Journal:  J Transl Med       Date:  2005-09-20       Impact factor: 5.531

3.  Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.

Authors:  Patricia Kleinpeter; Laetitia Fend; Christine Thioudellet; Michel Geist; Nathalie Sfrontato; Véronique Koerper; Catherine Fahrner; Doris Schmitt; Murielle Gantzer; Christelle Remy-Ziller; Renée Brandely; Dominique Villeval; Karola Rittner; Nathalie Silvestre; Philippe Erbs; Laurence Zitvogel; Eric Quéméneur; Xavier Préville; Jean-Baptiste Marchand
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

4.  By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Authors:  Patricia Kleinpeter; Christelle Remy-Ziller; Eline Winter; Murielle Gantzer; Virginie Nourtier; Juliette Kempf; Julie Hortelano; Doris Schmitt; Huguette Schultz; Michel Geist; Catherine Brua; Chantal Hoffmann; Yasmin Schlesinger; Dominique Villeval; Christine Thioudellet; Philippe Erbs; Johann Foloppe; Nathalie Silvestre; Laetitia Fend; Eric Quemeneur; Jean-Baptiste Marchand
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

Review 5.  Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.

Authors:  Roland E Kontermann; Guy Ungerechts; Dirk M Nettelbeck
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.